For example, the ATPase activity of SWI/SNF members BRG1 and BRM can be blocked by dual allosteric small-molecule inhibitors, BRM014 or orally bioavailable inhibitor FHD-286 (Figure 5A) in BRG1-deficient lung cancer, acute myeloid leukaemia and uveal melanoma models (Papillon et al., 2018; Rago et al., 2020; Vaswani et al., 2025). Here, SMARCA2 is linked to lung cancer.